Higher growth hormone levels (31.4 ± 6.7 ng/mL vs. 21.5 ± 7.2 ng/mL, p < 0.05), tumor size (11.9 ± 4.1 cm3 vs. 7.8 ± 3.5 cm3, p < 0.05), and tumor recurrence (22.6% vs. 12.9%) were seen in the high-SYT1 group compared to the low-SYT1 group. The gene discussed is GH1; the disease is neoplasm.